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tJ-107 (7.5 g) or matching placebo daily. the severity of 
OPn was assessed according to the Common toxicity Cri-
teria for adverse events at baseline, every 2 weeks until 
the 8th cycle, and every 4 weeks thereafter until the 26th 
week. the primary endpoint was the incidence of grade 2 
or greater OPn until the 8th cycle of chemotherapy.
Results analyses were done by intention to treat. eighty-
nine patients were randomly assigned to receive either tJ-
107 (n = 44) or placebo (n = 45) between May 2009 and 
March 2010. the incidence of grade 2 or greater OPn until 
the 8th cycle was 39 and 51 % in the tJ-107 and placebo 
groups, respectively (relative risk (rr), 0.76; 95 % CI, 
0.47–1.21). the incidence of grade 3 OPn was 7 % (tJ-
107) vs. 13 % (placebo) (0.51, 0.14–1.92). no concerns 
regarding toxicity emerged with tJ-107 treatment.
Conclusions tJ-107 appears to have an acceptable 
safety margin and a promising effect in delaying the onset 
of grade 2 or greater OPn without impairing FOlFOX 
efficacy.
Keywords goshajinkigan · Peripheral neuropathy · 
Double-blind randomized trial · Oxaliplatin · Colorectal 
cancer
Abstract 
Purpose Oxaliplatin-induced peripheral neurotoxicity 
(OPn) is frequent and potentially severe, but successful 
treatment of this condition is still an unmet clinical need. 
We aimed to determine whether treatment with goshajinki-
gan (tJ-107), a traditional Japanese medicine, is better than 
placebo in preventing OPn in patients with advanced or 
recurrent colorectal cancer patients treated with standard 
FOlFOX regimens.
Methods In this phase 2, randomized, double-blind, 
placebo-controlled study, patients undergoing oxaliplatin-
based chemotherapy were randomized to receive either oral 
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Introduction
Oxaliplatin is considered one of the gold standard chem-
otherapeutic agents for advanced colorectal cancers and 
for adjuvant chemotherapy. However, oxaliplatin-induced 
peripheral neurotoxicity (OPn) is extremely common 
with the incidence varying from 82 to 98 % [1–3]. Severe 
OPn occurs in 10 to 20 % of patients [1, 4], and some 
may require dose reductions and discontinuation of treat-
ment, potentially reducing the efficacy of chemotherapy 
and survival [5–7]. Despite considerable efforts to discover 
neuroprotective agents to prevent OPn [8], the best phar-
macologic strategy for the management of OPn remains 
controversial [9–11].
In Japan, tJ-107 (goshajinkigan), a traditional Japanese 
medicine (Kampo) [12], has been frequently prescribed to 
alleviate symptoms of diabetic peripheral neuropathy such 
as numbness, cold sensation, and paresthesias/dysesthesias 
[13–15]. We hypothesized that tJ-107 might be effec-
tive against OPn and retrospectively investigated its use 
in a pilot study of 90 patients with advanced colorectal 
cancer undergoing FOlFOX therapy [16]. Patients were 
treated with tJ-107, calcium (Ca) gluconate and magne-
sium (Mg) sulfate infusion, combination of tJ-107 and Ca/
Mg infusion, or chemotherapy alone. Our results showed 
that the group receiving tJ-107 with FOlFOX regimen 
experienced significant improvement in OPn and showed 
a favorable safety profile. We subsequently conducted a 
small, single-arm prospective study in 45 patients who 
were treated with modified FOlFOX6 for advanced colo-
rectal cancer, in which 22 patients receiving oral tJ-107 
reported lower incidence of grades 2 and 3 OPn than that 
in the control group [17]. Hence, this phase 2, randomized, 
double-blind, placebo-controlled, exploratory trial was ini-




this was an exploratory, randomized, phase 2 trial to evalu-
ate the efficacy of tJ-107 for preventing OPn in the gos-
hajinkigan Oxaliplatin neurotoxicity evaluation (gOne) 
study group conducted at 20 institutions in Japan [18].
eligibility criteria
Patients were eligible if they had histologically confirmed 
colorectal cancer and were scheduled to undergo chemo-
therapy with infusional 5-fluorouracil (5-FU), leucov-
orin (I-lV), and oxaliplatin (either FOlFOX4 or modi-
fied FOlFOX6 regimen). Patients had to have a good 
performance status (eCOg 0–1), adequate bone marrow 
function (WBC ≥ 3,000 and ≤12,000/mm3, neutrophil 
count ≥ 1,500/mm3, platelet count ≥100,000/mm3), renal 
function (serum creatinine level less than the institu-
tional upper limit of normal), and hepatic function (biliru-
bin ≤ 1.5 times institutional normal, aspartate aminotrans-
ferase, and alanine aminotransferase levels less than 2.5 
times the institutional upper limit of normal), life expec-
tancy ≥12 weeks, without evidence of clinical infection, 
and without preexisting peripheral neuropathy from any 
cause. exclusion criteria included prior exposure to chemo-
therapy, except for oral fluorinated pyrimidine derivatives 
or 5-FU/l-lV in an adjuvant setting, use of other Kampo 
medicines, history of severe hypersensitivity (allergy) to 
any medications, other active malignancies or a history 
of other malignancies within the past 5 years, congestive 
heart failure, diabetes, or a history of a hemorrhagic stroke. 
Patients who were pregnant or nursing, taking a neuro-
pathic pain medication, or receiving radiation were deemed 
ineligible.
this study was conducted in accordance with the Dec-
laration of Helsinki and the Japanese Ministry of Health, 
labour and Welfare guidelines, and informed consent was 
obtained from all participants. the study protocol was 
approved by the local Institutional review Board at each 
participating institution.
randomization and masking
eligible patients were centrally randomized by a computer-
generated allocation sequence in a 1:1 ratio to either tJ-
107 group or placebo group. Information regarding the 
necessary follow-up tests was then sent to the registration 
center at the non-profit organization epidemiological and 
Clinical research Information network (eCrIn). Patients, 
investigators, and data collectors were all blinded to treat-
ment allocation.
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Study medications
tJ-107 is a mixture of aqueous extracts from 10 crude herbs 
in fixed proportions (rehmanniae radix, 10.7 %; achyran-
this radix, 6.4 %; Corni Fructus, 6.4 %; Moutan Cortex, 
6.4 %; alismatis rhizome, 6.4 %; Dioscoreae rhizome, 
6.4 %; Plantaginis Semen, 6.4 %; Poria (Poria cocos Wolf), 
6.4 %; processed aconiti tuber, 2.1 %; and Cinnamomi 
Cortex, 2.1 %). the extract powder of tJ-107 is commer-
cially available in Japan and was obtained from tsumura 
& Co. (tokyo, Japan). Matching placebo (tsumura & Co.) 
was specifically manufactured for this clinical trial. the 
appearance, color, and odor of the placebo were well con-
trolled that both patients and clinicians were unable to dis-
tinguish this placebo from the original tJ-107. Dried pow-
der (2.5 g) of tJ-107 or placebo was administered orally 
three times a day before each meal (7.5 g/day).
treatment
Patients were randomly assigned to receive tJ-107 or pla-
cebo with either FOlFOX4 or mFOlFOX6 therapy. this 
treatment was initiated at the first delivery of FOlFOX and 
continued throughout the administration of chemotherapy 
and for 26 weeks beyond the completion of chemotherapy. 
Cycles of chemotherapy were given every 2 weeks until 
progressive disease or unacceptable toxicity occurred.
tJ-107 was given orally for 26 weeks starting on the day 
of oxaliplatin infusion. to avoid any possible influence on 
the assessment of neurotoxicity, Ca/Mg infusion was pro-
hibited only during the 26-week administration of tJ-107 
and not throughout the chemotherapy regimen. FOlFOX4 
therapy consisted of infusion of l-lV at 100 mg/m2 over 
2 h followed by 5-FU as a bolus (400 mg/m2) and a 22-h 
infusion of 5-FU (600 mg/m2) on day 1 and day 2, with 
infusion of oxaliplatin at 85 mg/m2 over 2 h on day 1. this 
regimen was repeated every 2 weeks. mFOlFOX6 therapy 
consisted of infusion of l-lV at 200 mg/m2 over 2 h fol-
lowed by 5-FU as a bolus (400 mg/m2) and a 46-h infusion 
of 5-FU (2,400 mg/m2) with an infusion of oxaliplatin at 
85 mg/m2 over 2 h on day 1. this regimen was repeated 
every 2 weeks.
adverse reactions including OPn were assessed at 
baseline (prior to starting FOlFOX + tJ-107 or FOl-
FOX + placebo), every 2 weeks until the 8th cycle and 
every 4 weeks thereafter until the 26th week according to 
the national Cancer Institute Common terminology Cri-
teria for adverse events (nCI-CtCae v3.0). the severity 
of neurotoxicity was assessed by the study clinicians who 
were blinded to treatment allocation and used the sensory 
neuropathy items in nCI-CtCae v3.0, which describe the 
four grades as follows: grade 1, loss of deep tendon reflexes 
or paresthesia, including tingling, but not interfering with 
function; grade 2, objective sensory alteration or paresthe-
sia, including tingling, interfering with function, but not 
interfering with activities of daily living (aDl); grade 3, 
sensory alteration or paresthesia interfering with aDl; and 
grade 4, permanent sensory losses that are disabling. In 
addition, patients rated their symptoms on a 0–4 scale using 
the Functional assessment of Cancer therapy/gynecologi-
cal Oncology group-neurotoxicity (FaCt/gOg-ntx-12) 
score at screening, at baseline, and before each chemo-
therapy treatment. these subjective ratings were indepen-
dently evaluated from the clinician-rated CtCae grading. 
the follow-up period was 1 year after registration of the 
last patient.
Statistical analysis
the primary endpoint of this study was the incidence of 
grade 2 or greater OPn after 8 cycles of chemotherapy as 
assessed by the clinical investigators. the rate of incidence 
was compared between evaluable patients randomized to 
either the tJ-107 or the placebo group. the rate of occur-
rence of grade 2 or greater OPn was calculated for each 
group and compared using the chi-square test.
Secondary endpoints included the incidence and grading 
of OPn after each cycle, FaCt/gOg-ntx-12 score, time 
to occurrence of OPn, response rate to chemotherapy, and 
toxicity.
Previously, we found that the incidence of grade 2 or 
greater OPn was 15 and 45 % (tJ-107 vs placebo) from 
the start of oxaliplatin treatment until the completion of 
cycle 8 [16]. On the basis of this data, we determined that 
in order to detect with 80 % power while maintaining a 
significance level of 10 % in a two-sided test, 35 patients 
per group would be required to compare the two treatment 
groups with a chi-square test. to account for possible drop-
outs, a minimum of 40 patients were enrolled in each group 
(80 in total). randomization was achieved by using three 
strata: use of bevacizumab, the institution, and the presence 
of target lesions evaluated by response evaluation Cri-
teria in Solid tumors (reCISt) version 1.1. this trial is 
registered with the UMIn Clinical trials registry in Japan 
(UMIn000002211).
Results
a total of 93 patients were enrolled from May 1, 2009, 
to March 31, 2010. Of the 93 patients, 47 were assigned 
to the tJ-107 group and 46 to the placebo group. Four 
patients (3 receiving tJ-107 and 1 control) were with-
drawn before initiation of treatment and included in the 
intention-to-treat set analysis (Fig. 1). the remaining 89 
(96 %) patients were consequently assessable for efficacy 
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and toxicity. reasons for premature withdrawal were dis-
ease progression (6 patients), adverse events (4), medical 
reasons (4), patient request (2), and complete response, 
operation, or death (1 each). generally, demographic and 
background characteristics of the patients were well bal-
anced between the tJ-107 group (n = 44) and placebo 
group (n = 45) (P values ranging from 0.203–0.833) 
(table 1).
Incidence of OPn
Data on the incidence of grade 2 or greater OPn 
and grade 3 OPn until the 8th cycle are summarized 
(table 2). the incidence of grade 2 or greater OPn until 
the 8th cycle was 39 % in the tJ-107 group and 51 % in 
the placebo group (relative risk (rr) 0.76; 95 % confi-
dence interval (CI) 0.47–1.21). Similarly, the incidence 
of grade 3 OPn until the 8th cycle was 7 % in the tJ-107 
group and 13 % in the placebo group (rr 0.51; 95 %CI 
0.14–1.92).
the time to occurrence of grade 2 or greater OPn 
is shown in Fig. 2. In patients who developed grade 
2 or greater OPn, the median time to occurrence was 
5.5 months (95 %CI 4.1–n.a.) in the tJ-107 group and 
3.9 months (95 % CI 2.3–6.4) in the placebo group (rr 
0.65; 95 % CI 0.36–1.17). the median time to occur-
rence of grade 3 neurotoxicity was better controlled in the 
tJ-107 group (rr 0.71; 95 % CI 0.29–1.77). the median 
frequency of occurrence of OPn at 26 weeks was 54.1 
and 62.5 % (rr 0.86) in the tJ-107 and placebo groups, 
respectively.
When we stratified the patients based on FOlFOX 
regimen (i.e., FOlFOX4 vs. mFOlFOX6) and performed 
a subanalysis to determine whether there was a difference 
in the effects of tJ-107 on the occurrence of OPn, we 
found that there was no significant difference between 
Fig. 1  COnSOrt diagram







 Male 23 25 0.833
 Female 21 20
age
 Median 67 61 0.215
 range 40–88 36–82
Performance status
 0 40 44 0.203
 1 4 1
Primary tumor
 Colon 28 30 0.826
 rectum 16 15
Chemotherapy
 First-line 36 35 0.793
 adjuvant 8 10
Table 2  Oxaliplatin-induced peripheral neurotoxicity until the 8th 
cycle
Oxaliplatin-induced peripheral neurotoxicity until the 8th cycle
tJ-107
(N = 44) (%)
Placebo
(N = 45) (%)
relative risk [95 %CI]
grade ≥2 39 51 0.76 [0.47–1.21]
grade 3 7 13 0.51 [0.14–1.92]
Fig. 2  time to occurrence of grade 2 or greater neurotoxicity. Solid 
line tJ-107, broken line Placebo
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treatment groups albeit the small sample size in each 
group.
the median FaCt scores of the tJ-107 and placebo 
groups were 6.0 vs. 9.0 (P = 0.421) at 8 weeks and 7.0 vs. 
10.5 (P = 0.151) at 26 weeks (table 3). although the dif-
ferences were statistically unremarkable, patients receiving 
tJ-107 tended to show milder symptoms of neurotoxicity 
than those who received placebo.
tumor response rate
the anti-tumor effect was assessed in 27 (tJ-107) and 
23 (placebo) patients who had a target lesion at the time 
of enrollment. Bevacizumab was administered in 74 % 
(20/27) and 74 % (17/23) of patients in the tJ-107 group 
and the placebo group, respectively (table 4).
the overall chemotherapy response rates were 56 % 
in the tJ-107 group and 48 % in the placebo group. In 
addition, 89 % (tJ-107) and 96 % (placebo) of patients 
demonstrated disease control (complete response, partial 
response, or stable disease) (table 4).
toxicity assessment
tJ-107 used in this study appeared to be well tolerated. 
there were no significant differences between the two 
groups in terms of toxicity. the most common adverse 
events likely caused by the chemotherapy were anorexia, 
fatigue, nausea, and stomatitis, which were reported at sim-
ilar rates from patients of both groups (table 5). Vomiting 
was significantly suppressed in patients on tJ-107 com-
pared with controls (9 vs. 29 %, P = 0.029). In the context 
of systemic chemotherapy, most of these events were likely 
related to chemotherapy-induced toxicity, yet none of them 
were considered tJ-107 related. eighteen hematologic tox-
icity events of grade 3 or greater (15 neutropenia) in the 
placebo group were reported, and 12 events (10 neutrope-
nia) were noted in the tJ-107 group (table 6). One patient 
in the placebo group died as a direct result of progressive 
disease.
Table 3  Median FaCt/gOg-ntx-12 score
* FaCt/gOg-ntx-12: Functional assessment of Cancer therapy/






8 weeks 6.0 9.0 0.421
26 weeks 7.0 10.5 0.151






Complete response (Cr) 1 1
Partial response (Pr) 14 10
Stable disease (SD) 9 11
Progression disease (PD) 3 1















Table 5  Incidence of adverse events
all grades
tJ-107 (N = 44) 
(%)
Placebo (N = 45) 
(%)
P value
Fatigue 25 (57) 26 (58) 1.000
anorexia 27 (61) 22 (49) 0.289
nausea 20 (45) 28 (62) 0.139
Vomiting 4 (9) 13 (29) 0.029
Stomatitis 19 (43) 16 (36) 0.519
Diarrhea 15 (34) 10 (22) 0.245
Hand-food  
syndrome
11 (25) 7 (16) 0.302
allergic reaction 8 (18) 4 (9) 0.230
Febrile  
neutropenia
0 (0) 2 (4) 0.494
Constipation 2 (5) 2 (4) 1.000
Ileus 0 (0) 2 (4) 0.494
total Bilirubin 4 (9) 4 (9) 1.000
aSt 13 (30) 23 (51) 0.052
alt 10 (23) 19 (42) 0.070
alP 13(30) 19(42) 0.271
Table 6  Incidence of hematologic toxicity events
tJ-107
(N = 44) (%)
Placebo
(N = 45) (%)
P value
all grades
 leukopenia 21 (48) 27 (60) 0.291
 neutropenia 15 (34) 21 (47) 0.282
 anemia 30 (68) 31 (69) 1.000
 thrombocytopenia 12 (27) 15 (33) 0.646
grade ≥ 3
 leukopenia 1 (2) 2 (4) 1.000
 neutropenia 10 (23) 15 (33) 0.347
 anemia 1 (2) 1 (2) 1.000
 thrombocytopenia 0 (0) 0 (0) 1.000
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Discussion
this is the first placebo-controlled, randomized, explora-
tory study that assessed the efficacy of oral tJ-107 in the 
treatment of OPn in colorectal cancer patients undergoing 
oxaliplatin-based chemotherapy.
Our randomized, phase 2, exploratory trial using a pla-
cebo was designed to assess the potential success of oral 
tJ-107 in the phase 3 setting, rather than provide solid data 
on its efficacy. results of this study showed promising rel-
ative risk that support the clinical activity of oral tJ-107 
against OPn, particularly acute cold-associated neuropa-
thy, in patients who received FOlFOX therapy (FOlFOX4 
or mFOlFOX6) for colorectal cancer without imposing 
negative impact on oxaliplatin-based anti-tumor effect. 
additionally, tJ-107 did not cause any adverse effects dur-
ing the trial. Our findings, which showed improvement in 
both CtCae grades and patient-rated FaCt/gOg-ntx 
scores, suggest that tJ-107 delays the occurrence of grade 
2 or greater OPn during active treatment although its thera-
peutic effect may plateau after 6.5 months of continuous 
administration and that the development of neurotoxicity 
was not correlated with the completion of oxaliplatin treat-
ment. given the difficulty of generating statistically robust 
data with a small sample size, we surmised that our data 
warrant further investigation in a large phase 3 setting.
as an exploratory, phase 2 trial of patients with 
advanced or relapsed colorectal cancer (some with unre-
sectable cancer), we conducted the endpoint assessment 
after 8 cycles rather than at treatment completion on the 
basis of a previous study that reported the high likelihood 
of detecting the side effects of oxaliplatin after 8 cycles 
[19], suggesting that this time point may be critical for 
deciding whether to continue oxaliplatin-based chemo-
therapy. Furthermore, a postmarketing drug surveillance of 
tJ-107 in Japan has shown that the median time to occur-
rence of grade 3 neuropathy with motor disorder was after 
8 cycles. taken together, these data suggest the evaluation 
of neuropathy at its peak incidence after 8 cycles to be clin-
ically more meaningful than delaying the evaluation until 
treatment completion.
tJ-107 is a complex drug containing 10 medicinal 
herbs with a wide spectrum of pharmacologic actions [16]. 
experimental studies have shown that tJ-107 relieves neu-
rologic symptoms of diabetic peripheral neuropathy such 
as cold hyperalgesia and mechanical allodynia [13–15] pri-
marily by the action of its analgesic component, detoxified 
aconiti tuber. the purported mechanisms by which this 
component works in concert with the other components of 
tJ-107 to exert a neuroprotective effect include (1) evok-
ing the release of dynorphin and activating endogenous 
κ-opioid receptors to improve numbness or paresthesia [20, 
21], (2) decreasing the release of transmitter proteins and 
sensory receptors associated with C-fiber nociceptor acti-
vation [22, 23], and (3) promoting nitric oxide production 
to improve blood supply to the nerves [24]. Furthermore, 
a recent experimental study has demonstrated that tJ-107 
ameliorates the pain associated with OPn in rats without 
affecting the anti-tumor activity of oxaliplatin [25], which 
is in line with our findings. Interestingly, we also found that 
tJ-107 significantly decreased vomiting compared with 
placebo. the precise mechanism remains unclear but one 
of the components of tJ-107, Poria (Poria cocos Wolf), has 
shown an antiemetic effect through 5-Ht3a receptor inhi-
bition [26, 27].
according to the Multicenter International Study of 
Oxaliplatin, 5-Fluorouracil and leucovorin in the adjuvant 
treatment of Colon Cancer (MOSaIC) study, the reported 
incidences of OPn were as follows: grade 1 (48 %), grade 
2 (32 %), and grade 3 (12 %) [1]. In the present study, the 
incidence of grade 2 and grade 3 OPn in the placebo group 
until the 8th cycle was 51 % and 13 %, respectively, which 
is consistent with the MOSaIC study [1]. there was no 
marked difference in time to treatment failure in this study. 
One possible explanation for this is that even if greater than 
grade 2 OPn had occurred once, oxaliplatin administration 
was continued so long as OPn was downgraded to grade 
2 on the day of administration. another possibility is that 
patients may not acknowledge or report neuropathic symp-
toms for fear of missing out on an effective cancer treat-
ment. thus, it seems imperative to discover an agent that 
has sufficient evidence to decrease OPn development.
Many agents have been tested, in both humans and 
experimental animals, to ameliorate OPn [28]. recently, 
the antidepressant drug venlafaxine, which is also used to 
manage pain associated with diabetic peripheral neuropa-
thy, has been reported to significantly decrease the inci-
dence of acute OPn in a placebo-controlled, randomized, 
phase 3 trial; however, grade 1–2 vomiting was observed 
more frequently in patients who received venlafaxine [29]. 
tJ-107 has also been used to treat painful diabetic periph-
eral neuropathy [13–15], but our study showed that tJ-107 
significantly decreased vomiting compared to placebo, and 
other common adverse events due to chemotherapy did not 
worsen with tJ-107 treatment. effective preventive treat-
ments must not only mitigate neurotoxicity but must also 
preserve the antineoplastic effect of chemotherapeutic 
drugs. In this study, no between-group differences were 
found in response rates to chemotherapy or in the survival 
rates, suggesting that tJ-107 had no influence on FOlFOX 
therapy. Moreover, tJ-107 is an easily administered alter-
native that does not produce serious adverse effect, render-
ing it conducive to increasing compliance among patients 
and health care practitioners in a cancer treatment setting.
this is the first, randomized, phase 2, exploratory trial 
of tJ-107 whose study design itself is comparable to that 
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of an older phase 3 trial design. the primary objective of 
this phase 2 trial study was to determine whether our find-
ings would warrant validation in a phase 3 setting and not 
necessarily to obtain concrete data that show statistical sig-
nificance. In other words, our aim was to define the char-
acteristics of tJ-107 against OPn relative to placebo in 
order to refine the design of a phase 3 trial. through this 
study, we were able to obtain a more accurate estimation of 
sample size and confirm that tJ-107 was similar to placebo 
in terms of toxicity despite the small sample size, and tJ-
107 prevented the progression and development of severe 
neurotoxicity, one of the primary dose-limiting factors of 
oxaliplatin-based chemotherapy. taken together, our find-
ings suggest that this trial served as an effective platform 
for testing the efficacy of a novel agent like tJ-107 in 
oncology and for designing and accelerating the transition 
from phase 2 to a large phase 3 trial that employs objective 
measures.
Conclusions
Findings from this phase 2, exploratory trial suggest that 
oral tJ-107 has acceptable margins of safety and tolerabil-
ity and a promising effect in delaying the onset of grade 
2 or greater OPn in colorectal cancer patients treated with 
oxaliplatin. 
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